Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics of patients with LVV

From: Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis

VariableGCA, n = 12TAK, n = 8HC for GCA, n = 5HC for TAK, n = 5
Baseline demographic
 Age at diagnosis, years (IQR)71 (69–77)47 (32–56)72 (61–78)50 (28–58)
 Male, n (%)7 (58)4 (50)2 (40)1 (20)
 Time from symptom onset to diagnosis, months (IQR)2.5 (1.2–4.8)3.6 (2.7–12)  
 Body mass index at diagnosis, kg/m2 (IQR)18 (17–22)23 (17–24)  
 Smoking, n (%)6 (50)3 (38)  
Comorbidities
 Hypertension, n (%)4 (33)1 (13)  
 Diabetes mellitus, n (%)2 (17)0 (0)  
 Dyslipidemia, n (%)5 (42)1 (13)  
 Chronic kidney disease, n (%)1 (8.3)2 (25)  
 PMR, n (%)6 (50)0 (0)  
 IBD, n (%)0 (0)2 (25)  
Laboratory tests
 ESR, mm/h (IQR)120 (115–134)70 (56–109)  
 CRP, mg/dL (IQR)4.6 (2.2–8.2)4.8 (2.1–7.9)  
Arterial involvement
 GCA: cranial/LV, n8/4  
 TAK: type I/IIa/IIb/III/IV/V, n1/1/1/1/0/4  
Induction treatment
 Initial dose of PSL, mg (IQR)50 (40–59)60 (50–60)  
 Biologic agents, n (%)TCZ: 5 (42)TCZ, 4 (50); IFX, 2 (25) (25)  
 Relapse, n (%)4 (33)3 (38)  
 Surgery, n (%)0 (0)3 (38)  
 Relapse/surgery, n (%)4 (33)5 (63)  
 Time to first relapse/surgery, months (IQR)6.0 ± 4.03.6 ± 2.2  
  1. LVV large vessel vasculitis, GCA giant cell arteritis, TAK Takayasu arteritis, HC healthy control, PMR polymyalgia rheumatica, IBD inflammatory bowel syndrome, ESR erythrocyte sedimentation rate, CRP C-reactive protein, LV large vessel, PSL prednisolone